Editorial 2: Efficacy and Safety Outcomes in Clinical Trials of Proprotein Convertase Subtilisin-Kexin (PCSK) Type 9 Inhibitors in Coronary Artery Disease
Publisher: Nova Science Publishers, Inc.
ISSN: 1556-4002
Source: World Heart Journal, Vol., Iss., 2017-01, pp. : 15-18
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Related content
JOURNAL OF THE AMERICAN HEART ASSOCIATION, Vol. 5, Iss. 5, 2016-05 ,pp. :